Emergent BioSolutions | EBS - Trade Creditors


Emergent BioSolutions reported $112.2M in Trade Creditors for its fiscal quarter ending in December of 2023.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
Akebia Therapeutics USD 8.39M 12.8M Mar/2026
ALKERMES USD 142.86M 40.5M Jun/2026
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
Amarin USD 18.8M 29.36M Jun/2026
ANI Pharmaceuticals USD 69.69M 7.11M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Coherus Biosciences USD 9.91M 14.98M Dec/2025
Emergent BioSolutions USD 112.2M 500K Dec/2023
Exelixis USD 24.15M 5.47M Mar/2026
Glaxosmithkline GBP 14.34B 6.39B Mar/2026
Heron Therapeutics USD 8.97M 24K Mar/2026
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
Ironwood Pharmaceuticals USD 3.24M 339K Mar/2026
Lexicon Pharmaceuticals USD 3M 87K Mar/2026
Lonza CHF 471M 3M Dec/2024
Merck USD 3.86B 541M Mar/2026
Moderna USD 167M 6M Jun/2026
Myriad Genetics USD 30.4M 2.2M Jun/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Pacira USD 17.51M 3.5M Jun/2026
Pfizer USD 4.58B 75M Jun/2026
PTC Therapeutics USD 40.45M 14.96M Jun/2026
Sanofi EUR 23.6B 888M Jun/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
United Therapeutics USD 498.3M 491.2M Mar/2026
Vanda Pharmaceuticals USD 39.09M 33.28M Dec/2024